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Tumor of the Stomach in an Elderly Patientq,qqFig. 1. Esophagogastroduodenoscopy showed a 2-cm ulcerative lesion at the greater
curvature side of the middle corpus (arrow).To the Editor:
The simultaneous occurrence of the adenocarcinoma and
gastrointestinal stromal tumor (GIST) in the stomach is rare that
only a few cases have been documented in the literature.
A 79-year-old man presented to our hospital with tarry stools of
1 day’s duration. Physical examination was unremarkable, with the
exception of pale conjunctiva. Esophagogastroduodenoscopy
showed an ulcerative lesion at the greater curvature of the middle
corpus measuring 2  0.5 cm (Fig. 1). Biopsy revealed moderately
differentiated adenocarcinoma.
Subtotal gastrectomy and Billroth II gastrojejunal anastomosis
were performed. A 1  1 cm subserosal tumor was found at the
anterior wall of the upper body of the stomach, 10 cm proximal
to the ulcerative lesion during surgery, so this tumor was included
in the resected specimen. Microscopic examination of the subser-
osal tumor revealed low-risk spindle cell type GIST involving the
muscularis propria of the stomach. The GIST showed interlacing
fascicles of bland, uniform spindle cells with pale eosinophilic cyto-
plasm. On immunohistochemical examination, the lesion stained
diffusely and strongly for CD 117 and DOG-1, but was negative for
S100 protein (Fig. 2).
Postoperative ileus and gastrointestinal bleeding occurred and
were managed conservatively. The patient was discharged on post-
operative day 61. Adjuvant chemotherapy for adenocarcinoma and
target therapy for GIST were not given.
Abdominal computed tomography, upper gastrointestinal imag-
ing, and esophagogastroduodenoscopy 12 months after surgery
showed no signs of recurrence.
Adenocarcinoma is the most common malignancy in the stom-
ach, whereas GIST is a rare disease, with an incidence of 10–20
per 1 million cases. GISTs were formerly considered variants of
smooth muscle tumors: leiomyomas if benign and leiomyosarco-
mas if malignant. Until 1998, Hirota reported that GISTs contained
activating CD 117 mutations, which play a central role in its
pathogenesis1.q All contributing authors declare no conﬂicts of interest.
qq This case report has been presented in part at the Conference of Taiwan Surgical C
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http://dx.doi.org/10.1016/j.ijge.2013.01.017Only a few cases of simultaneous development of adenocarci-
noma and GIST in the stomach had been report. In our case, gastric
adenocarcinoma and GIST arise from different regions of stomach;
collision tumors have also been reported. No convincing explana-
tion given for this coexistence except for simple coincident. In
1970, Sugimura et al2 used a rat model to explain the development
of simultaneous adenocarcinoma and leiomyosarcoma in the stom-
ach induced by carcinogens, and showed that interaction of the car-
cinogens may induce the development of tumors of different
histiotypes in the same organ.
Treatment of both tumors varies, and is tailored according to the
staging and risk. Target therapy with imatinib for GIST in high-risk
patients improved the disease-free survival. Most patients with aonference in Taipei, Taiwan (March 2011).
cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. (A) Poorly differentiated adenocarcinoma (100). (B) Spindle cell type gastrointestinal stromal tumor (100). The GIST shows interlacing fascicles of bland, uniform spindle
cells with pale eosinophilic cytoplasm. (C) Strongly positive for CD 117. (D) Strongly positive for DOG-1.
Letter to the Editor242low risk for GIST have favorable outcomes following surgery and
thus are not candidates for adjuvant imatinib3.References
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